The following research analysts cover Destiny Pharma.
|Mark Brewer, finnCap||+44(0)20 7220 0500|
|Andy Smith, Equity Development||+44(0)20 7065 2690|
Please click on links below to access coverage published:
Analyst research from finnCap can be obtained by registering on the link above
27 September 2021 – Destiny Pharma – China progress – CMS establishes new dermal programme
For further commentary and interviews, please visit the Destiny Pharma page at Proactive Investors on the link above